Purdue Pharma LP
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1892-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.purduepharma.com
Clinical Trials
58
Active:0
Completed:43
Trial Phases
4 Phases
Phase 1:16
Phase 2:8
Phase 3:29
+1 more phases
Drug Approvals
11
SFDA:6
FDA:5
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (57 trials with phase data)• Click on a phase to view related trials
Phase 3
29 (50.9%)Phase 1
16 (28.1%)Phase 2
8 (14.0%)Phase 4
4 (7.0%)Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg
Phase 1
Completed
- Conditions
- Opioid Overdose
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 24
- Registration Number
- NCT06719986
- Locations
- 🇺🇸
Ohio Clinical Trials, Columbus, Ohio, United States
Clinical Outcomes From Nalmefene
Phase 4
Withdrawn
- Conditions
- Opioid Overdose
- Interventions
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Purdue Pharma LP
- Registration Number
- NCT05808881
Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 103
- Registration Number
- NCT04987762
- Locations
- 🇺🇸
Preferred Research Partners, Inc., Little Rock, Arkansas, United States
🇺🇸MCB Clinical Research Centers, LLC, Colorado Springs, Colorado, United States
🇺🇸Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)
Phase 4
Terminated
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 267
- Registration Number
- NCT04507204
- Locations
- 🇺🇸
Harmonex, Inc., Dothan, Alabama, United States
🇺🇸Southern California Research LLC, Beverly Hills, California, United States
🇺🇸CT Clinical Research, Cromwell, Connecticut, United States
Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System
Completed
- Conditions
- Chronic Pain
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 135
- Registration Number
- NCT03299556
- Locations
- 🇺🇸
Geisinger Health System, Danville, Pennsylvania, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
No news found